Last Updated: August 14, 2026

Patent: 11,078,296


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,078,296
Title:Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
Abstract:Provided are heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain. At least one of the heterodimers comprises amino acid modifications in the Cand/or Cdomains, amino acid modifications in the Vand/or Vdomains or a combination thereof. The modified amino acid residues are part of the interface between the light chain and heavy chain and are modified in order to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a mammalian cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer preferentially pairs with the second light chain rather than first.
Inventor(s):Corper Adam Louis, Urosev Dunja, Tom-Yew Stacey A. L., Bleile Dustin Weyland Blue, Spreter Von Kreudenstein Thomas, Dixit Surjit, Lario Paula Irene, Sanches Mario
Assignee:ZYMEWORKS INC.
Application Number:US15896170
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

United States Patent 11,078,296: Claim Scope, Validity Risk, and US Patent Landscape Impact

No analysis can be produced because the provided inputs do not include the patent’s claim text. The claims are referenced but not included, and a patent landscape assessment depends on claim-level details (independent claim limitations, dependent claim structure, priority dates, and priority subject matter) to map infringement, design-around options, and relevant prior art.

What are the claims of US Patent 11,078,296?

Answer: Not provided.

Why claim text is required to map scope

Answer: Without the actual claim language, the analysis cannot identify:

  • The precise technical limitations (composition, formulation, dosing regimen, device structure, method steps, process parameters, or use conditions)
  • The claim category (composition of matter, method of use, manufacturing method, apparatus, or formulation)
  • The novelty hooks needed to evaluate anticipation/obviousness and to shortlist closest prior art

How does US Patent 11,078,296 claim novelty and what would infringement require?

Answer: Not provided.

What claim elements drive infringement

Answer: Not provided.

What patents protect the same invention space as US 11,078,296?

Answer: Not provided.

How to identify overlapping US estates (data needed)

Answer: Not provided.

When does US Patent 11,078,296 expire and when can generics challenge?

Answer: Not provided.

What typically controls exclusivity timing in the US

Answer: Not provided.

What is the Orange Book status for the drug implicated by US 11,078,296?

Answer: Not provided.

Which patents are listed for FDA approval

Answer: Not provided.

Which companies are likely affected by US 11,078,296?

Answer: Not provided.

How to map real-world competitors and litigants

Answer: Not provided.

What patent litigation affects US 11,078,296?

Answer: Not provided.

How to evaluate settlement and estoppel risk

Answer: Not provided.

How strong is the patent estate around US 11,078,296 (continuations, continuations-in-part, continuations)?

Answer: Not provided.

Which claim classes typically survive in parallel prosecutions

Answer: Not provided.

Which generic entry risks exist for products covered by US 11,078,296?

Answer: Not provided.

Design-around pathways that depend on specific claim limitations

Answer: Not provided.

How does US Patent 11,078,296 compare with nearby patents in the same technology cluster?

Answer: Not provided.

What “nearby” means in practice

Answer: Not provided.

What formulations or manufacturing methods are protected by US 11,078,296?

Answer: Not provided.

Method-of-use and process claim mapping

Answer: Not provided.

Key Takeaways

Answer: Not provided.

FAQs

  1. What claim elements determine whether a generic infringes US 11,078,296?
    Answer: Not provided.
  2. Can competitors design around US 11,078,296 by changing formulation parameters?
    Answer: Not provided.
  3. Does US 11,078,296 cover device features or only chemical compositions?
    Answer: Not provided.
  4. What prior art categories are most relevant to challenging US 11,078,296 in US district court?
    Answer: Not provided.
  5. How does US 11,078,296 affect Paragraph IV or 505(b)(2) strategy for the relevant FDA product?
    Answer: Not provided.

References

  1. Not provided.

More… ↓

⤷  Start Trial

Details for Patent 11,078,296

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Octapharma Pharmazeutika Produktionsges.m.b.h. CUTAQUIG immune globulin subcutaneous (human)-hipp Solution 125668 December 12, 2018 ⤷  Start Trial 2038-02-14
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.